Status:
COMPLETED
Safety and Efficacy of Vaniprevir (MK7009) Administered With Pegylated-Interferon and Ribavirin (MK-7009-007)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Hepatitis C
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
A study to evaluate how effective different levels of Vaniprevir (MK-7009), when administered with Pegylated-Interferon (Peg-IFN) and Ribavirin, are at achieving rapid viral response (RVR) i.e., undet...
Eligibility Criteria
Inclusion
- Patient has chronic Genotype 1 Hepatitis C infection
Exclusion
- Subject has been previously treated for HCV
- Has Human Immunodeficiency Virus (HIV)
- Has Hepatitis B
- Has a history of clinically significant medical condition that may interfere with the study (e.g., stroke or chronic seizures or major neurological disorder) or is contraindicated for treatment with peg-IFN and Ribavirin
Key Trial Info
Start Date :
July 25 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 14 2010
Estimated Enrollment :
95 Patients enrolled
Trial Details
Trial ID
NCT00704184
Start Date
July 25 2008
End Date
April 14 2010
Last Update
October 9 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.